EUVIMEDEUVIMED entdecken
Crossref

Deferoxamine mesylate enhances mandibular advancement‐induced condylar osteogenesis by promoting H‐type angiogenesis

Yun Hu iD, Hegang Li iD

Journal of Oral Rehabilitation · 2023

DOI: 10.1111/joor.13410 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Oral Rehabilitation, 2023. Verfasst von Yun Hu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthodontics, Stomatological Hospital, Southern Medical University, Guangzhou, China. Hauptthemen laut MEDLINE: Mandibular Condyle, Mandibular Advancement. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: Scientific Research Talent Cultivation Project of the Stomatological Hospital, Southern Medical University, Guangdong Basic and Applied Basic Research Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The effect of functional orthopaedic treatment for mandibular deficiency relies on mandibular advancement (MA)‐induced condylar new bone formation. However, this is not easy to achieve, especially in non‐growing patients. Therefore, how to obtain reliable MA‐induced condylar osteogenesis is a subject much worthy of study.

Objective

To investigate whether deferoxamine mesylate (DFM) enhances MA‐induced condylar osteogenesis in middle‐aged mice.

Methods

Forty 30‐week‐old male C57BL/6J mice were randomly divided into 4 groups: the control (Ctrl), DFM, MA + Ctrl and MA + DFM groups. After a 4‐week experimental period, femurs, tibias and condyles were collected for morphological, micro‐computed tomography and histological evaluation.

Results

For long bones, DFM reversed osteoporosis in middle‐aged mice by promoting H‐type angiogenesis. For mandibular condyles, MA promoted condylar osteogenesis in middle‐aged mice, thereby allowing the mandible to achieve a stable protruding position. In addition, DFM enhanced the volume and quality of MA‐induced condylar new bone formation. Furthermore, histological analysis revealed that DFM enhanced MA‐induced condylar subchondral ossification. Mechanistically, it was confirmed that DFM increased the number of H‐type vessels and their coupled Osterix + osteoprogenitors by upregulating the hypoxia‐inducible factor (HIF)‐1α signalling pathway, thereby enhancing MA‐induced condylar osteogenesis.

Conclusion

Applying DFM to enhance MA‐induced condylar osteogenesis through H‐type angiogenesis is expected to be an effective strategy to achieve favourable functional orthopaedic treatment effectiveness in non‐growing patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mandibular CondyleMandibular AdvancementMaleMiceAnimalsOsteogenesisDeferoxamineX-Ray MicrotomographyMice, Inbred C57BL

Stichwörter der Autor:innen

H-type vesselsangiogenesisdeferoxamine mesylatemandibular advancementmandibular condyleosteogenesis

Substanzen

Deferoxamine

Autor:innen und Institutionen

  • Department of Orthodontics, Stomatological Hospital, Southern Medical University, Guangzhou, China.

ORCID-Profile: Yun Hu, Hegang Li

Förderung

  • Scientific Research Talent Cultivation Project of the Stomatological Hospital
  • Southern Medical University
  • Guangdong Basic and Applied Basic Research Fund

Zitieren

APA

Hu, Y., & Li, H. (2023). Deferoxamine mesylate enhances mandibular advancement‐induced condylar osteogenesis by promoting H‐type angiogenesis. Journal of Oral Rehabilitation. https://doi.org/10.1111/joor.13410

Vancouver

Hu Y, Li H. Deferoxamine mesylate enhances mandibular advancement‐induced condylar osteogenesis by promoting H‐type angiogenesis. Journal of Oral Rehabilitation. 2023. doi:10.1111/joor.13410

BibTeX
@article{Hu2023,
  author = {Hu, Yun and Li, Hegang},
  title = {Deferoxamine mesylate enhances mandibular advancement‐induced condylar osteogenesis by promoting H‐type angiogenesis},
  journal = {Journal of Oral Rehabilitation},
  year = {2023},
  doi = {10.1111/joor.13410}
}
Kostenlos starten →